<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>APTIOM- eslicarbazepine acetate tablet </strong><br><strong>APTIOM- eslicarbazepine acetate 
			 </strong><br>Sunovion Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use APTIOM safely and effectively.  See full prescribing information for APTIOM.  <br>APTIOM<span class="Sup">®</span> (eslicarbazepine acetate) tablets, for oral use<br>Initial U.S. Approval: 2013
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" width="83.900%">
<col align="left" width="16.100%">
<tbody class="Headless">
<tr>
<td align="left" valign="top">Indications and Usage (<a href="#s1">1</a>)
</td>
<td align="right" valign="top">08/2015
</td>
</tr>
<tr>
<td align="left" valign="top">Dosage and Administration (<a href="#s2">2</a>)
</td>
<td align="right" valign="top">08/2015
</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">APTIOM is indicated for the treatment of partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> as monotherapy or adjunctive therapy. (<a href="#s1">1</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>The recommended initial dosage of APTIOM is 400 mg once daily. For some patients, treatment may be initiated at 800 mg once daily if the need for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> reduction outweighs an increased risk of adverse reactions. (<a href="#s4">2.2</a>)
</li>
<li>Increase the dose in weekly increments of 400 mg to 600 mg once daily, based on clinical response and tolerability, to a recommended maintenance dosage of 800 mg to 1600 mg once daily.  (<a href="#s4">2.2</a>)
</li>
<li>Patients with Moderate or Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Reduce dosage by 50%. (<a href="#s6">2.4</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets:  200 mg, 400 mg, 600 mg, 800 mg (<a href="#s9">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to eslicarbazepine acetate or oxcarbazepine. (<a href="#s10">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation: Monitor for suicidal thoughts or behavior. (<a href="#s12">5.1</a>)
</li>
<li>Serious Dermatologic Reactions, Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS), <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>: Monitor and discontinue if another cause cannot be established. (<a href="#s13">5.2</a>, <a href="#s14">5.3</a>, <a href="#s15">5.4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>: Monitor sodium levels in patients at risk or patients experiencing <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> symptoms. (<a href="#s16">5.5</a>)
</li>
<li>Neurological Adverse Reactions: Monitor for <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, disturbance in gait and coordination, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, cognitive dysfunction, and visual changes. Use caution when driving or operating machinery. (<a href="#s17">5.6</a>)
</li>
<li>Withdrawal of APTIOM: Withdraw APTIOM gradually to minimize the risk of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency and <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. (<a href="#s8">2.6</a>, <a href="#s23">5.7</a>)
</li>
<li>Drug Induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span>: Discontinue APTIOM in patients with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or evidence of significant <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>. (<a href="#s24">5.8</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions in patients receiving APTIOM (≥4% and ≥2% greater than placebo): <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>. (<a href="#s27">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sunovion at 1-877-737-7226 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Carbamazepine: May need dose adjustment for APTIOM or carbamazepine. (<a href="#s5">2.3</a>, <a href="#s17">5.6</a>, <a href="#s34">7.2</a>, <a href="#s35">7.3</a>)
</li>
<li>Phenytoin: Higher dosage of APTIOM may be necessary and dose adjustment may be needed for phenytoin. (<a href="#s5">2.3</a>, <a href="#s34">7.2</a>, <a href="#s35">7.3</a>)
</li>
<li>Phenobarbital or Primidone:  Higher dosage of APTIOM may be necessary. (<a href="#s5">2.3</a>, <a href="#s34">7.2</a>)
</li>
<li>Hormonal Contraceptives:  APTIOM may decrease the effectiveness of hormonal contraceptives. (<a href="#s35">7.3</a>, <a href="#s36">7.4</a>, <a href="#s47">8.9</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Based on animal data, may cause fetal harm. (<a href="#s38">8.1</a>)
 </p></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="XmChange"></span>1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Important Administration Instructions
</a></h2>
<h2><a href="#section-2.2" class="toc"><span class="XmChange"></span>2.2 General Dosing Recommendations
</a></h2>
<h2><a href="#section-2.3" class="toc"><span class="XmChange"></span>2.3 Dosage Modifications with Other Antiepileptic Drugs
</a></h2>
<h2><a href="#section-2.4" class="toc"><span class="XmChange"></span>2.4 Dosage Modifications in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Discontinuation of APTIOM
</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Serious Dermatologic Reactions
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Neurological Adverse Reactions
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Withdrawal of AEDs
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Drug Induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Abnormal <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span>
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 General Information
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for Other AEDs to Affect Eslicarbazepine
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Potential for APTIOM to Affect Other Drugs
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Oral Contraceptives
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Gender
</a></h2>
<h2><a href="#section-8.8" class="toc">8.9 Females of Reproductive Potential
</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance
</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse
</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE
</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Signs, Symptoms, and Laboratory Findings of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute Overdose</span> in Humans
</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Treatment or Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>
</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-12.2" class="toc">12.2  Pharmacodynamics
</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Monotherapy for Partial-Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h2><a href="#section-14.2" class="toc">14.2  Adjunctive Therapy for Partial-Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</a></h2>
<h1><a href="#section-15" class="toc">15 REFERENCES
</a></h1>
<h1><a href="#section-16" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-17" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1 style="border-left:1px solid;">
<span class="XmChange"></span>1 INDICATIONS AND USAGE
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>APTIOM (eslicarbazepine acetate) is indicated for the treatment of partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> as monotherapy or adjunctive therapy.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Important Administration Instructions
</h2>
<p class="First">Instruct patients to administer APTIOM either as whole or as crushed tablets.  Instruct patients to take APTIOM either with or without food.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s4"></a><a name="section-2.2"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.2 General Dosing Recommendations
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>The recommended initial dosage of APTIOM is 400 mg once daily. For some patients, treatment may be initiated at 800 mg once daily if the need for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> reduction outweighs an increased risk of adverse reactions during initiation <span class="Italics">[see Adverse Reactions (<a href="#s27">6.1</a>)]</span>. Dosage should be increased in weekly increments of 400 mg to 600 mg, based on clinical response and tolerability, to a recommended maintenance dosage of 800 mg to 1600 mg once daily. For patients on APTIOM monotherapy, the 800 mg once daily maintenance dose should generally be considered in patients who are unable to tolerate a 1200 mg daily dose. For patients on APTIOM adjunctive therapy, the 1600 mg daily dose should generally be considered in patients who did not achieve a satisfactory response with a 1200 mg daily dose.  
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-2.3"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.3 Dosage Modifications with Other Antiepileptic Drugs
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>Some adverse reactions occur more frequently when patients take APTIOM adjunctively with carbamazepine <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.6</a>)]</span>.   However, carbamazepine reduces the plasma concentration of eslicarbazepine <span class="Italics">[see Drug Interactions (<a href="#s34">7.2</a>)]</span>. When APTIOM and carbamazepine are taken concomitantly, the dose of APTIOM or carbamazepine may need to be adjusted based on efficacy and tolerability.  For patients taking other enzyme-inducing AEDs (i.e., phenobarbital, phenytoin, and primidone), higher doses of APTIOM may be needed <span class="Italics">[see Drug Interactions (<a href="#s34">7.2</a>)].</span></p>
<p style="border-left:1px solid;"><span class="XmChange"></span>APTIOM should not be taken as an adjunctive therapy with oxcarbazepine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-2.4"></a><p></p>
<h2 style="border-left:1px solid;">
<span class="XmChange"></span>2.4 Dosage Modifications in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>In patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (i.e., creatinine clearance &lt; 50 mL/min), the initial, titration, and maintenance dosages should generally be reduced by 50%. Titration and maintenance dosages may be adjusted according to clinical response <span class="Italics">[see Use in Specific Populations (<a href="#s44">8.6</a>) and Clinical Pharmacology (<a href="#s59">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Dose adjustments are not required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Use of APTIOM in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been studied, and use in these patients is not recommended <span class="Italics">[see Use in Specific Populations (<a href="#s45">8.7</a>) and Clinical Pharmacology (<a href="#s59">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Discontinuation of APTIOM
</h2>
<p class="First">When discontinuing APTIOM, reduce the dosage gradually and avoid abrupt discontinuation in order to minimize the risk of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency and <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> <span class="Italics">[see Warnings and Precautions (<a href="#s23">5.7</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s9"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">APTIOM tablets are available in the following shapes and color (<a href="#t1">Table 1</a>) with respective one-sided engraving:
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: APTIOM Tablet Presentations
</span></caption>
<col align="left" width="22.175%">
<col align="left" width="30.250%">
<col align="left" width="24.250%">
<col align="left" width="23.325%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet Strength</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet Color/Shape</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet Markings</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Functional Score</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">200 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">White oblong
</td>
<td class="Botrule Rrule" align="center" valign="top">ESL 200
</td>
<td class="Botrule Rrule" align="center" valign="top">Yes
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">400 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">White circular bi-convex
</td>
<td class="Botrule Rrule" align="center" valign="top">ESL 400
</td>
<td class="Botrule Rrule" align="center" valign="top">No
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">600 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">White oblong
</td>
<td class="Botrule Rrule" align="center" valign="top">ESL 600
</td>
<td class="Botrule Rrule" align="center" valign="top">Yes
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">800 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">White oblong
</td>
<td class="Botrule Rrule" align="center" valign="top">ESL 800
</td>
<td class="Botrule Rrule" align="center" valign="top">Yes
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">APTIOM is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to eslicarbazepine acetate or oxcarbazepine <span class="Italics">[see Warnings and Precautions (<a href="#s13">5.2</a>, <a href="#s14">5.3</a>, and <a href="#s15">5.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s11"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation
</h2>
<p class="First">Antiepileptic drugs (AEDs), including APTIOM, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number of events is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.
</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5-100 years) in the clinical trials analyzed.
</p>
<p><a href="#t2">Table 2</a> shows absolute and relative risk by indication for all evaluated AEDs.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Risk of Suicidal Thoughts or Behaviors by Indication for Antiepileptic Drugs in the Pooled Analysis
</span></caption>
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<col align="left" width="20.000%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Indication
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Placebo Patients with Events Per 1000 Patients
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Drug Patients with Events Per 1000 Patients
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Relative Risk:  Incidence of Events in Drug Patients/Incidence in Placebo Patients
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top">Risk Differences: Additional Drug Patients with Events Per 1000 Patients
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.0
</td>
<td class="Botrule Rrule" align="left" valign="top">3.4
</td>
<td class="Botrule Rrule" align="left" valign="top">3.5
</td>
<td class="Botrule Rrule" align="left" valign="top">2.4
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Psychiatric
</td>
<td class="Botrule Rrule" align="left" valign="top">5.7
</td>
<td class="Botrule Rrule" align="left" valign="top">8.5
</td>
<td class="Botrule Rrule" align="left" valign="top">1.5
</td>
<td class="Botrule Rrule" align="left" valign="top">2.9
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Other
</td>
<td class="Botrule Rrule" align="left" valign="top">1.0
</td>
<td class="Botrule Rrule" align="left" valign="top">1.8
</td>
<td class="Botrule Rrule" align="left" valign="top">1.9
</td>
<td class="Botrule Rrule" align="left" valign="top">0.9
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Total
</td>
<td class="Botrule Rrule" align="left" valign="top">2.4
</td>
<td class="Botrule Rrule" align="left" valign="top">4.3
</td>
<td class="Botrule Rrule" align="left" valign="top">1.8
</td>
<td class="Botrule Rrule" align="left" valign="top">1.9
</td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials in patients with psychiatric or other conditions, but the absolute risk differences were similar for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.
</p>
<p>Anyone considering prescribing APTIOM or any other AED must balance this risk with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
</p>
<p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; any unusual changes in mood or behavior; or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Serious Dermatologic Reactions
</h2>
<p class="First">Serious dermatologic reactions including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS) have been reported in association with APTIOM use.  Serious and sometimes fatal dermatologic reactions, including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN) and SJS, have been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM.   The reporting rate of these reactions associated with oxcarbazepine use exceeds the background incidence rate estimates by a factor of 3- to 10-fold.  Risk factors for development of serious dermatologic reactions with APTIOM use have not been identified.
</p>
<p>If a patient develops a dermatologic reaction while taking APTIOM, discontinue APTIOM use, unless the reaction is clearly not drug-related.  Patients with a prior dermatologic reaction with either oxcarbazepine or APTIOM should not be treated with APTIOM <span class="Italics">[see Contraindications (<a href="#s10">4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS), also known as Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, has been reported in patients taking APTIOM. DRESS may be fatal or life-threatening. DRESS typically, although not exclusively, presents with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and/or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, in association with other organ system involvement, such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, hematological abnormalities, <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>, or <span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span> sometimes resembling an acute <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>. <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved. It is important to note that early manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, may be present even though <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is not evident. If such signs or symptoms are present, the patient should be evaluated immediately.  APTIOM should be discontinued and not be resumed if an alternative etiology for the signs or symptoms cannot be established.  Patients with a prior DRESS reaction with either oxcarbazepine or APTIOM should not be treated with APTIOM <span class="Italics">[see Contraindications (<a href="#s10">4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>
</h2>
<p class="First">Rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been reported in patients taking APTIOM.  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> can be fatal.  If a patient develops any of these reactions after treatment with APTIOM, the drug should be discontinued.  Patients with a prior anaphylactic-type reaction with either oxcarbazepine or APTIOM should not be treated with APTIOM <span class="Italics">[see Contraindications (<a href="#s10">4</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>
</h2>
<p class="First">Clinically significant <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (sodium &lt;125 mEq/L) can develop in patients taking APTIOM.  In the controlled adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials, 4/415 patients (1.0%) treated with 800 mg and 6/410 (1.5%) patients treated with 1200 mg of APTIOM had at least one serum sodium value less than 125 mEq/L, compared to none of the patients assigned to placebo.  A higher percentage of APTIOM-treated patients (5.1%) than placebo-treated patients (0.7%) experienced decreases in sodium values of more than 10 mEq/L.  These effects were dose-related and generally appeared within the first 8 weeks of treatment (as early as after 3 days).  Serious, life-threatening complications were reported with APTIOM-associated <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (as low as 112 mEq/L) including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, severe <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> leading to <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, severe <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait instability</span>, and injury.  Some patients required hospitalization and discontinuation of APTIOM.  Concurrent <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span> was also present in patients with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.  Depending on the severity of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, the dose of APTIOM may need to be reduced or discontinued. <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> was also observed in monotherapy trials.
</p>
<p>Measurement of serum sodium and chloride levels should be considered during maintenance treatment with APTIOM, particularly if the patient is receiving other medications known to decrease serum sodium levels and should be performed if symptoms of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> develop (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, or increase in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency or severity).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Neurological Adverse Reactions
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.6.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and Disturbance in Gait and Coordination</span></p>
<p>APTIOM causes dose-related increases in adverse reactions related to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and disturbance in gait and coordination (<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, and abnormal coordination) <span class="Italics">[see Adverse Reactions (<a href="#s27">6.1</a>)]</span>. In controlled adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials, these events were reported in 26% and 38% of patients randomized to receive APTIOM at doses of 800 mg and 1200 mg/day, respectively, compared to 12% of placebo-treated patients.  Events related to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and disturbance in gait and coordination were more often serious in APTIOM-treated patients than in placebo-treated patients (2% vs. 0%), and more often led to study withdrawal in APTIOM-treated patients than in placebo-treated patients (9% vs. 0.7%).  There was an increased risk of these adverse reactions during the titration period (compared to the maintenance period) and there also may be an increased risk of these adverse reactions in patients 60 years of age and older compared to younger adults.  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> also occurred with these events. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> and disturbance in gait and coordination were also observed in monotherapy trials.
</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was greater with the concomitant use of APTIOM and carbamazepine compared to the use of APTIOM without carbamazepine (up to 37% vs. 19%, respectively).  Therefore, consider dosage modifications of both APTIOM and carbamazepine if these drugs are used concomitantly <span class="Italics">[see Dosage and Administration (<a href="#s5">2.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.6.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></span></p>
<p>APTIOM causes dose-dependent increases in <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>-related adverse reactions (<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="438134" conceptname="Hypersomnia">hypersomnia</span>, sedation, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>).  In the controlled adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials, these events were reported in 13% of placebo patients, 16% of patients randomized to receive 800 mg/day APTIOM, and 28% of patients randomized to receive 1200 mg/day APTIOM. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>-related events were serious in 0.3% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 3% of APTIOM-treated patients (and 0.7% of placebo-treated patients). <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> were also observed in monotherapy trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-5.6.3"></a><p></p>
<p class="First"><span class="Underline">Cognitive Dysfunction</span></p>
<p>APTIOM causes dose-dependent increases in cognitive dysfunction-related events (<span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">memory impairment</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="440424" conceptname="Aphasia">aphasia</span>, speech disorder, slowness of thought, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="4160898" conceptname="Motor retardation">psychomotor retardation</span>).  In the controlled adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials, these events were reported in 1% of placebo patients, 4% of patients randomized to receive 800 mg/day APTIOM, and 7% of patients randomized to receive 1200 mg/day APTIOM. Cognitive dysfunction-related events were serious in 0.2% of APTIOM-treated patients (and 0.2% of placebo patients) and led to discontinuation in 1% of APTIOM-treated patients (and 0.5% of placebo-treated patients). Cognitive dysfunction events were also observed in monotherapy trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-5.6.4"></a><p></p>
<p class="First"><span class="Underline">Visual Changes</span></p>
<p>APTIOM causes dose-dependent increases in events related to visual changes including <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and impaired vision.  In the controlled adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials, these events were reported in 16% of patients randomized to receive APTIOM compared to 6% of placebo patients. Eye events were serious in 0.7% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 4% of APTIOM-treated patients (and 0.2% of placebo-treated patients).   There was an increased risk of these adverse reactions during the titration period (compared to the maintenance period) and also in patients 60 years of age and older (compared to younger adults).  The incidence of <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> was greater with the concomitant use of APTIOM and carbamazepine compared to the use of APTIOM without carbamazepine (up to 16% vs. 6%, respectively) <span class="Italics">[see Dosage and Administration (<a href="#s5">2.3</a>)]</span>. Events related to visual changes were also observed in monotherapy trials.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-5.6.5"></a><p></p>
<p class="First"><span class="Underline">Hazardous Activities</span></p>
<p>Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of APTIOM is known.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Withdrawal of AEDs
</h2>
<p class="First">As with all antiepileptic drugs, APTIOM should be withdrawn gradually because of the risk of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency and <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Drug Induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span>
</h2>
<p class="First">Hepatic effects, ranging from mild to moderate elevations in transaminases (&gt;3 times the upper limit of normal) to rare cases with concomitant elevations of total bilirubin (&gt;2 times the upper limit of normal) have been reported with APTIOM use.  Baseline evaluations of liver laboratory tests are recommended. The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.  APTIOM should be discontinued in patients with <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or other evidence of significant <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> (e.g., laboratory evidence).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Abnormal <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span>
</h2>
<p class="First">Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM.  These changes were not associated with other abnormal <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> suggesting <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.  Abnormal <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">thyroid function tests</span> should be clinically evaluated.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s26"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following adverse reactions are described in more detail in the <span class="Italics">Warnings and Precautions</span> section of the label:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.1</a>)]</span>
</li>
<li>Serious Dermatologic Reactions <span class="Italics">[see Warnings and Precautions (<a href="#s13">5.2</a>)]</span>
</li>
<li>Drug Reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> and Systemic Symptoms (DRESS)/Multiorgan <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <span class="Italics">[see Warnings and Precautions (<a href="#s14">5.3</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.4</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.5</a>)]</span>
</li>
<li>Neurological Adverse Reactions <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.6</a>)]</span>
</li>
<li>Drug Induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">Liver Injury</span> <span class="Italics">[see Warnings and Precautions (<a href="#s24">5.8</a>)]</span>
</li>
<li>Abnormal <span class="product-label-link" type="condition" conceptid="4261836" conceptname="Thyroid panel">Thyroid Function Tests</span> <span class="Italics">[see Warnings and Precautions (<a href="#s25">5.9</a>)]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<p>In monotherapy trials in patients with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [Study 1 and Study 2, <span class="Italics">see Clinical Studies (<a href="#s77">14.1</a>)</span>]<span class="Italics">,</span> 365 patients received APTIOM, of whom 225 were treated for longer than 12 months and 134 for longer than 24 months. Of the patients in those trials, 95% were between 18 and 65 years old; 48% were male, and 84% were Caucasian. Across controlled and uncontrolled trials in patients  receiving adjunctive therapy for partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, 1195 patients received APTIOM, of whom 586 were treated for longer than 6 months and 462 for longer than 12 months. In the placebo controlled adjunctive therapy trials in patients with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (Study 3, Study 4 and Study 5), 1021 patients received APTIOM.  Of the patients in those trials, approximately 95% were between 18 and 60 years old, approximately 50% were male, and approximately 80% were Caucasian.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Monotherapy Historical Control Trials</span></p>
<p>In the monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials (Study 1 and Study 2), 13% of patients randomized to receive APTIOM at the recommended doses of 1200 mg and 1600 mg once daily discontinued from the trials as a result of an adverse event. The adverse reaction most commonly (≥1% on APTIOM) leading to discontinuation was <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.
</p>
<p>Adverse reactions observed in these studies were generally similar to those observed and attributed to drug in adjunctive placebo-controlled studies. Because these studies did not include a placebo control group, causality could not be established.
</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> were all reported at lower incidences during the AED Withdrawal Phase and Monotherapy Phase compared with the Titration Phase.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Adjunctive Therapy Controlled Trials</span></p>
<p>In the controlled adjunctive therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials (Study 3, Study 4, and Study 5)<span class="Italics">,</span> the rate of discontinuation as a result of any adverse reaction was 14% for the 800 mg dose, 25% for the 1200 mg dose, and 7% in subjects randomized to placebo. The adverse reactions most commonly (≥1% in any APTIOM treatment group, and greater than placebo) leading to discontinuation, in descending order of frequency, were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.
</p>
<p>The most frequently reported adverse reactions in patients receiving APTIOM at doses of 800 mg or 1200 mg (≥4% and ≥2% greater than placebo) were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>.
</p>
<p><a href="#t3">Table 3</a> gives the incidence of adverse reactions that occurred in ≥2% of subjects with partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in any APTIOM treatment group and for which the incidence was greater than placebo during the controlled clinical trials. Adverse reactions during titration were less frequent for patients who began therapy at an initial dose of 400 mg for 1 week and then increased to 800 mg compared to patients who initiated therapy at 800 mg.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Adverse Reactions Incidence in Pooled Controlled Clinical Trials of Adjunctive Therapy in Adults (Events ≥2% of Patients in the APTIOM 800 mg or 1200 mg Dose Group and More Frequent Than in the Placebo Group)
</span></caption>
<col align="left" width="40.350%">
<col align="left" width="14.450%">
<col align="left" width="20.250%">
<col align="left" width="24.950%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Placebo</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">APTIOM</span></th>
</tr>
<tr>
<th class="Botrule Rrule" align="center" valign="middle"><span class="Bold">800 mg</span></th>
<th class="Botrule Rrule" align="center" valign="middle"><span class="Bold">1200 mg</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">(N=426)</span><br><span class="Bold">%</span>
</th>
<th class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">(N=415)</span><br><span class="Bold">%</span>
</th>
<th class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">(N=410)</span><br><span class="Bold">%</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">Ear and labyrinth disorders<br>     <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>6
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span><br>     <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span><br>     <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span><br>     <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Visual impairment</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2<br>1<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>9<br>6<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>11<br>5<br>1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span><br>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span><br>     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>     <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">5<br>3<br>3<br>1<br>1<br>&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">10<br>6<br>4<br>2<br>2<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">16<br>10<br>2<br>2<br>2<br>&lt;1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">General disorders and administration site conditions
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span><br>     <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait disturbance</span><br>     <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4<br>2<br>&lt;1<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">4<br>2<br>2<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">7<br>3<br>2<br>1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span><br>     <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">3
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Metabolism and nutrition disorders
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span><br>     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span><br>     <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span><br>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>     <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span><br>     <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">Balance disorder</span><br>     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span><br>     <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">Dysarthria</span><br>     <span class="product-label-link" type="condition" conceptid="4304008" conceptname="Memory impairment">Memory impairment</span><br>     <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>9<br>8<br>9<br>2<br>&lt;1<br>1<br>0<br>&lt;1<br>&lt;1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>20<br>11<br>13<br>4<br>3<br>2<br>1<br>1<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>28<br>18<br>15<br>6<br>3<br>4<br>2<br>2<br>2
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Psychiatric disorders<br>     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span><br>     <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1<br>2
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>3<br>2
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>
</td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
<td class="Botrule Rrule" align="center" valign="top">2
</td>
<td class="Botrule Rrule" align="center" valign="top">1
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Skin and subcutaneous tissue disorders<br>     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>3
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span><br>     <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>1
</td>
<td class="Botrule Rrule" align="center" valign="top">
<br>2
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Underline">Other Adverse Reactions with APTIOM Use</span></p>
<p>Compared to placebo, APTIOM use was associated with slightly higher frequencies of decreases in hemoglobin and hematocrit, increases in total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, and LDL, and increases in creatine phosphokinase.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Underline">Adverse Reactions Based on Gender and Race</span></p>
<p>No significant gender differences were noted in the incidence of adverse reactions.  Although there were few non-Caucasian patients, no differences in the incidences of adverse reactions compared to Caucasian patients were observed.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s32"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.1"></a><p></p>
<h2>7.1 General Information
</h2>
<p class="First">Several AEDs (e.g., carbamazepine, phenobarbital, phenytoin, and primidone) can induce enzymes that metabolize APTIOM and can cause decreased plasma concentrations of eslicarbazepine (see <a href="#fig1">Figure 1</a>).
</p>
<p>APTIOM can inhibit CYP2C19, which can cause increased plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., phenytoin, clobazam, and omeprazole). <span class="Italics">In vivo</span> studies suggest that APTIOM can induce CYP3A4, decreasing plasma concentrations of drugs that are metabolized by this isoenzyme (e.g., simvastatin) (see <a href="#fig2a">Figure 2</a>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for Other AEDs to Affect Eslicarbazepine
</h2>
<p class="First">The potential impact of other AEDs on the systemic exposure (area under the curve, AUC) of eslicarbazepine, the active metabolite of APTIOM, is shown in <a href="#fig1">Figure 1</a>:
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1: Potential Impact of Other AEDs on AUC of Eslicarbazepine</span></p>
<p><a name="f01"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Potential for APTIOM to Affect Other Drugs
</h2>
<p class="First">The potential impact of APTIOM on the systemic exposure (AUC) of other drugs (including AEDs) is shown in <a href="#fig2a">Figures 2a</a> and <a href="#fig2b">2b</a>:
</p>
<p><a name="fig2a"></a><span class="Bold">Figure 2a: Potential Impact of APTIOM on the AUC of AEDs</span></p>
<p><a name="f02"></a><img alt="Figure 2a
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-02.jpg"></p>
<p><a name="fig2b"></a><span class="Bold">Figure 2b: Potential Impact of APTIOM on the AUC of Non-AEDs</span></p>
<p><a name="f03"></a><img alt="Figure 2b
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-03.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Oral Contraceptives
</h2>
<p class="First">Because concomitant use of APTIOM and ethinylestradiol and levonorgestrel is associated with lower plasma levels of these hormones, females of reproductive potential should use additional or alternative non-hormonal birth control.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s37"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s38"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women. In oral studies conducted in pregnant mice, rats, and rabbits, eslicarbazepine acetate demonstrated developmental toxicity, including <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> (mice), embryolethality (rats), and <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span>, at clinically relevant doses. APTIOM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>When eslicarbazepine acetate was orally administered (150, 350, 650 mg/kg/day) to pregnant mice throughout organogenesis, increased incidences of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> was observed at all doses and <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> was observed at the mid and high doses. A no-effect dose for adverse developmental effects was not identified. At the lowest dose tested, plasma eslicarbazepine exposure (C<span class="Sub">max</span>, AUC) is less than that in humans at the maximum recommended human dose (MRHD, 1600 mg/day).
</p>
<p>Oral administration of eslicarbazepine acetate (40, 160, 320 mg/kg/day) to pregnant rabbits throughout organogenesis resulted in <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> and increased incidences of skeletal variations at the mid and high doses. The no-effect dose (40 mg/kg/day) is less than the MRHD on a mg/m<span class="Sup">2</span> basis.
</p>
<p>Oral administration to pregnant rats (65, 125, 250 mg/kg/day) throughout organogenesis resulted in embryolethality at all doses, increased incidences of skeletal variations at the mid and high doses, and <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> at the high dose. The lowest dose tested (65 mg/kg/day) is less than the MRHD on a mg/m<span class="Sup">2</span> basis.
</p>
<p>When eslicarbazepine acetate was orally administered to female mice during pregnancy and lactation (150, 350, 650 mg/kg/day), the gestation period was prolonged at the highest dose tested. In offspring, a persistent reduction in offspring body weight and delayed physical development and sexual maturation were observed at the mid and high doses. The lowest dose tested (150 mg/kg/day) is less than the MRHD on a mg/m<span class="Sup">2</span> basis.
</p>
<p>When eslicarbazepine acetate was orally administered (65, 125, 250 mg/kg/day) to rats during pregnancy and lactation, reduced offspring body weight was seen at the mid and high doses. Delayed sexual maturation and a neurological deficit (decreased motor coordination) were observed at the highest dose tested. The no-effect dose for adverse developmental effects (65 mg/kg/day) is less than the MRHD on a mg/m<span class="Sup">2</span> basis.
</p>
<p>The rat data are of uncertain relevance to humans because of differences in metabolic profile between species.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Registry</span></p>
<p>Physicians are advised to recommend that pregnant patients taking APTIOM enroll in the North American Antiepileptic Drug Pregnancy Registry. This can be done by calling 1-888-233-2334 (toll-free), and must be done by patients themselves. Information on the registry can also be found at the website http://www.aedpregnancyregistry.org/.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s41"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Eslicarbazepine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from APTIOM, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s42"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">Safety and effectiveness in patients below 18 years of age have not been established.
</p>
<p>In a juvenile animal study in which eslicarbazepine acetate (40, 60, 160 mg/kg/day) was orally administered to young dogs for 10 months starting on postnatal day 21, mortality and evidence of immunotoxicity (bone marrow hypocellularity and lymphoid tissue depletion) were observed at all doses. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> were seen at the highest dose tested. Adverse effects on bone growth (decreased bone mineral content and density) were seen in females at all doses at the end of the dosing period, but not at the end of a 2-month recovery period. None of these findings were reported in adult dogs dosed with eslicarbazepine acetate for up to 12 months in duration. A no-effect dose for adverse effects on juvenile dogs was not identified.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s43"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">There were insufficient numbers of patients ≥65 years old enrolled in the controlled adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials (N=15) to determine the efficacy of APTIOM in this patient population.  The pharmacokinetics of APTIOM were evaluated in elderly healthy subjects (N=12) (<a href="#fig3">Figure 3</a>). Although the pharmacokinetics of eslicarbazepine are not affected by age independently, dose selection should take in consideration the greater frequency of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and other concomitant medical conditions and drug therapies in the elderly patient. Dose adjustment is necessary if CrCl is &lt;50 mL/min <span class="Italics">[see Clinical Pharmacology (<a href="#s59">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Clearance of eslicarbazepine is decreased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> and is correlated with creatinine clearance. Dosage adjustment is necessary in patients with CrCl&lt;50 mL/min (<a href="#fig3">Figure 3</a>) <span class="Italics">[see Dosage and Administration (<a href="#s6">2.4</a>) and Clinical Pharmacology (<a href="#s59">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-8.6"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Dose adjustments are not required in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#fig3">Figure 3</a>).  Use of APTIOM in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been evaluated, and use in these patients is not recommended <span class="Italics">[see Clinical Pharmacology (<a href="#s59">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Gender
</h2>
<p class="First">No dosage adjustment is recommended on the basis of gender (<a href="#fig3">Figure 3</a>) <span class="Italics">[see Clinical Pharmacology (<a href="#s59">12.3</a>)].</span></p>
<p><a name="fig3"></a><span class="Bold">Figure 3: Impact of Intrinsic Factors on AUC of Eslicarbazepine</span></p>
<p><a name="f04"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-04.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-8.8"></a><p></p>
<h2>8.9 Females of Reproductive Potential
</h2>
<p class="First">Because concomitant use of APTIOM and ethinylestradiol and levonorgestrel is associated with lower plasma levels of these hormones, females of reproductive potential should use additional or alternative non-hormonal birth control <span class="Italics">[see Drug Interactions (<a href="#s35">7.3</a>, <a href="#s36">7.4</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s48"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<div class="Section" data-sectionCode="34085-1">
<a name="s49"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance
</h2>
<p class="First">APTIOM is not a controlled substance.
</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="s50"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse
</h2>
<p class="First">Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological or physiological effects. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span>, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug addiction</span> are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> (for example, abuse may not be accompanied by physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>) <span class="Italics">[see Drug Abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span> (<a href="#s51">9.3</a>)].</span></p>
<p>In a human abuse study in recreational sedative abusers APTIOM showed no evidence of abuse. In Phase 1, 1.5% of the healthy volunteers taking APTIOM reported <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> compared to 0.4% taking placebo.
</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="s51"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span>
</h2>
<p class="First">Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug.
</p>
<p>The potential for APTIOM to produce withdrawal symptoms has not been adequately evaluated.  In general, antiepileptic drugs should not be abruptly discontinued in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> because of the risk of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency and <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s52"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-10.1"></a><p></p>
<h2>10.1 Signs, Symptoms, and Laboratory Findings of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute Overdose</span> in Humans
</h2>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are consistent with the known adverse reactions of APTIOM and include <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (sometimes severe), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, oral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, walking difficulties, and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>. The maximum dosage studied in open-label monotherapy treatment following withdrawal of concomitant AEDs was 2400 mg once daily.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-10.2"></a><p></p>
<h2>10.2 Treatment or Management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span>
</h2>
<p class="First">There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with APTIOM. Symptomatic and supportive treatment should be administered as appropriate. Removal of the drug by gastric lavage and/or inactivation by administering activated charcoal should be considered.
</p>
<p>Standard hemodialysis procedures result in partial clearance of APTIOM. Hemodialysis may be considered based on the patient's clinical state or in patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s55"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">The chemical name of APTIOM (eslicarbazepine acetate) is (S)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. APTIOM is a dibenz[b,f]azepine-5-carboxamide derivative. Its molecular formula is C<span class="Sub">17</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">3</span> and its molecular weight is 296.32. The chemical structure is:
</p>
<div class="Figure">
<a name="f05"></a><img alt="Chemical Structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-05.jpg">
</div>
<p>APTIOM is a white to off-white, odorless crystalline solid. It is insoluble in hexane, very slightly soluble in aqueous solvents and soluble in organic solvents such as acetone, acetonitrile, and methanol.
</p>
<p>Each APTIOM tablet contains 200 mg, 400 mg, 600 mg or 800 mg of eslicarbazepine acetate and the following inactive ingredients: povidone, croscarmellose sodium, and magnesium stearate.<br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s56"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s57"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">APTIOM is extensively converted to eslicarbazepine, which is considered to be responsible for therapeutic effects in humans. The precise mechanism(s) by which eslicarbazepine exerts anticonvulsant activity is unknown but is thought to involve inhibition of voltage-gated sodium channels.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s58"></a><a name="section-12.2"></a><p></p>
<h2>12.2  Pharmacodynamics
</h2>
<p class="First">The effect of APTIOM on cardiac repolarization was evaluated in a randomized, double-blind, placebo- and active-controlled 4-period crossover trial in healthy adult men and women. Subjects received APTIOM 1200 mg once daily × 5 days, APTIOM 2400 mg once daily × 5 days, an active-control, moxifloxacin 400 mg × 1 dose on Day 5, and placebo once daily × 5 days. At both doses of APTIOM, no significant effect on the QTc interval was detected.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s59"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<p class="First">The pharmacokinetics of eslicarbazepine is linear and dose-proportional in the dose range of 400 mg to 1600 mg once daily, both in healthy subjects and patients. The apparent half-life of eslicarbazepine in plasma was 13-20 hours in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients. Steady-state plasma concentrations are attained after 4 to 5 days of once daily dosing.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Underline">Absorption, Distribution, Metabolism, and Excretion</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-12.3.1.1"></a><p></p>
<p class="First"><span class="Italics">Absorption</span></p>
<p>APTIOM is mostly undetectable (0.01% of the systemic exposure) after oral administration. Eslicarbazepine, the major metabolite, is primarily responsible for the pharmacological effect of APTIOM. Peak plasma concentrations (C<span class="Sub">max</span>) of eslicarbazepine are attained at 1-4 hours post-dose.  Eslicarbazepine is highly bioavailable, because the amount of eslicarbazepine and glucuronide metabolites recovered in urine corresponded to more than 90% of an APTIOM dose. Food has no effect on the pharmacokinetics of eslicarbazepine after oral administration of APTIOM.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-12.3.1.2"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>The binding of eslicarbazepine to plasma proteins is relatively low (&lt;40%) and independent of concentration.  <span class="Italics">In vitro</span> studies have shown that plasma protein binding was not relevantly affected by the presence of warfarin, diazepam, digoxin, phenytoin, or tolbutamide.  Similarly, the binding of warfarin, diazepam, digoxin, phenytoin or tolbutamide was not significantly affected by the presence of eslicarbazepine. The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-12.3.1.3"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>APTIOM is rapidly and extensively metabolized to its major active metabolite eslicarbazepine by hydrolytic first-pass metabolism.  Eslicarbazepine corresponds to 91% of systemic exposure. The systemic exposure to minor active metabolites of (R)-licarbazepine is 5% and oxcarbazepine is 1%. The inactive glucuronides of these active metabolites correspond to approximately 3% of systemic exposure.
</p>
<p>In <span class="Italics">i</span><span class="Italics">n vitro</span> studies in human liver microsomes, eslicarbazepine had no clinically relevant inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, and CYP3A4, and only a moderate inhibitory effect on CYP2C19. Studies with eslicarbazepine in fresh human hepatocytes showed no induction of enzymes involved in glucuronidation and sulfation of 7-hydroxy-coumarin. A mild activation of UGT1A1-mediated glucuronidation was observed in human hepatic microsomes.
</p>
<p>No apparent autoinduction of metabolism has been observed with APTIOM in humans.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-12.3.1.4"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>APTIOM metabolites are eliminated from the systemic circulation primarily by renal excretion, in the unchanged and glucuronide conjugate forms. In total, eslicarbazepine and its glucuronide account for more than 90% of total metabolites excreted in urine, approximately two thirds in the unchanged form and one third as glucuronide conjugate. Other minor metabolites account for the remaining 10% excreted in the urine. In healthy subjects with normal renal function, the renal clearance of eslicarbazepine (approximately 20 mL/min) is substantially lower than glomerular filtration rate (80-120 mL/min), suggesting that renal tubular reabsorption occurs. The apparent plasma half-life of eslicarbazepine was 13-20 hours in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> patients <span class="Italics">[see Dosage and Administration (<a href="#s6">2.4</a>) and Use in Specific Populations (<a href="#s44">8.6</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Underline">Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s66"></a><a name="section-12.3.2.1"></a><p></p>
<p class="First"><span class="Italics">Elderly (≥65 years of age)</span></p>
<p>The pharmacokinetic profile of eslicarbazepine was unaffected in elderly subjects with creatinine clearance &gt;60 mL/min compared to healthy subjects (18-40 years) after single and repeated doses of 600 mg APTIOM during 8 days of dosing. No dose adjustment is necessary in adults based on age, if CrCl is ≥50 mL/min.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-12.3.2.2"></a><p></p>
<p class="First"><span class="Italics">Gender</span></p>
<p>Studies in healthy subjects and patients showed that pharmacokinetics of eslicarbazepine was not affected by gender.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-12.3.2.3"></a><p></p>
<p class="First"><span class="Italics">Race</span></p>
<p>No clinically significant effect of race (Caucasian N=849, Black N=53, Asian N=65, and Other N=51) on the pharmacokinetics of eslicarbazepine was noted in a population pharmacokinetic analysis of pooled data from the clinical studies.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-12.3.2.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>APTIOM metabolites are eliminated from the systemic circulation primarily by renal excretion. The extent of systemic exposure of eslicarbazepine following an 800 mg single dose was increased by 62% in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 50-80 mL/min), by 2-fold in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl 30-49 mL/min) and by 2.5-fold in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt;30 mL/min) in comparison to the healthy subjects (CrCl &gt;80 mL/min). Dosage adjustment is recommended in patients with creatinine clearance below 50 mL/min <span class="Italics">[see Dosage and Administration (<a href="#s6">2.4</a>) and Use in Specific Populations (<a href="#s44">8.6</a>)].</span></p>
<p>In patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, repeated hemodialysis removed APTIOM metabolites from systemic circulation.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-12.3.2.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics and metabolism of APTIOM was evaluated in healthy subjects and patients with moderate liver impairment (7-9 points on the Child-Pugh assessment) after multiple oral doses. Moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did not affect the pharmacokinetics of APTIOM. No dose adjustment is recommended in patients with mild to moderate liver impairment.
</p>
<p>The pharmacokinetics of APTIOM has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.
</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s71"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s72"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>In a two-year carcinogenicity study in mice, eslicarbazepine acetate was administered orally at doses of 100, 250, and 600 mg/kg/day. An increase in the incidence of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas was observed at 250 and 600 mg/kg/day in males and at 600 mg/kg/day in females. The dose not associated with an increase in tumors (100 mg/kg/day) is less than the maximum recommended human dose (MRHD) (1600 mg/day for monotherapy) on a mg/m<span class="Sup">2</span> basis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis</span></p>
<p>Eslicarbazepine acetate and eslicarbazepine were not mutagenic in the <span class="Italics">in vitro</span> Ames assay. In <span class="Italics">in vitro</span> assays in mammalian cells, eslicarbazepine acetate and eslicarbazepine were not clastogenic in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>; however, eslicarbazepine acetate was clastogenic in Chinese hamster ovary (CHO) cells, with and without metabolic activation. Eslicarbazepine acetate was positive in the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> <span class="Italics">tk</span> assay in the absence of metabolic activation. Eslicarbazepine acetate was not clastogenic in the <span class="Italics">in vivo</span> mouse micronucleus assay.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility</span></p>
<p>When eslicarbazepine acetate (150, 350, and 650 mg/kg/day) was orally administered to male and female mice prior to and throughout the mating period, and continuing in females to gestation day 6, there was an increase in embryolethality at all doses. The lowest dose tested is less than the MRHD on a mg/m<span class="Sup">2</span> basis.
</p>
<p>When eslicarbazepine acetate (65, 125, 250 mg/kg/day) was orally administered to male and female rats prior to and throughout the mating period, and continuing in females to implantation, lengthening of the estrus cycle was observed at the highest dose tested. The data in rats are of uncertain relevance to humans because of differences in metabolic profile between species.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s76"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-14.1"></a><p></p>
<h2>14.1 Monotherapy for Partial-Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First">The effectiveness of APTIOM as monotherapy for partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in two identical, dose-blinded historical control trials in a total of 365 patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (Study 1 and  Study 2). In these trials, patients were randomized in a 2:1 ratio to receive either APTIOM 1600 mg or 1200 mg once daily, and their responses were compared to those of a historical control group. The historical control methodology is described in a publication by French et al. <span class="Italics">[see References (<a href="#s79">15</a>)]</span>. The historical control consisted of a pooled analysis of the control groups from 8 trials of similar design, which utilized a subtherapeutic dose of an AED as a comparator. Statistical superiority to the historical control was considered to be demonstrated if the upper limit from a 2-sided 95% confidence interval for the percentage of patients meeting exit criteria in patients receiving APTIOM remained below the lower 95% prediction interval of 65% derived from the historical control data.
</p>
<p>In Study 1 and Study 2, patients ≥16 years of age experienced at least 4 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during the baseline period with no 28-day <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> free period while receiving 1 or 2 AEDs (both could not be sodium-channel blocking drugs, and at least one AED was limited to 2/3 of a typical dose). APTIOM was titrated over a 1- to 2-week period followed by the gradual withdrawal of the background AED over a 6-week period, followed by a 10-week monotherapy period.
</p>
<p>The exit criteria were one or more of the following: (1) an episode of <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, (2) emergence of a generalized tonic-clonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in patients who had not had one in the past 6 months, (3) doubling of average monthly <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> count during any 28 consecutive days, (4) doubling of highest consecutive 2-day <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency during the entire treatment phase, or (5) worsening of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> severity considered by the investigator to require intervention.  The primary endpoint was the cumulative 112-day exit rate in the efficacy population. Additionally, in Studies 1 and 2, if the discontinuation rate exceeded 10%, patients were randomly reassigned to be counted as exits.
</p>
<p>The most commonly used baseline AEDs were carbamazepine, levetiracetam, valproic acid, and lamotrigine. Oxcarbazepine was used as a baseline AED in 6.6% of patients.
</p>
<p>In Study 1, the Kaplan-Meier (K-M) estimate of the percentage of patients meeting at least 1 exit criterion was 29% (95% CI: 21%, 38%) in the 1600 mg group and 44% (95% CI 33%, 58%) in the 1200 mg group. In Study 2, the K-M estimate of the percentage of patients meeting at least 1 exit criterion was 13% (95% CI: 8%, 22%) in the 1600 mg group and 16% (95% CI: 8%, 29%) in the 1200 mg group. The upper limit of the of the 2-sided 95% CI of both doses in both trials were below the threshold of 65% derived from the historical control data, meeting the pre-specified criteria for efficacy (see <a href="#fig4">Figure 4</a>).
</p>
<p><a name="fig4"></a><span class="Bold">Figure 4: Kaplan-Meier Estimates of Cumulative 112-Day Exit Rates for Studies 1 and 2</span></p>
<p><a name="f06"></a><img alt="Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-06.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-14.2"></a><p></p>
<h2>14.2  Adjunctive Therapy for Partial-Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>
</h2>
<p class="First">The efficacy of APTIOM as adjunctive therapy in partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in three randomized, double-blind, placebo-controlled, multicenter trials in adult patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (Study 3, Study 4, and Study 5). Patients enrolled had partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> with or without secondary generalization and were not adequately controlled with 1 to 3 concomitant AEDs. During an 8-week baseline period, patients were required to have an average of ≥4 partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per 28 days with no <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>-free period exceeding 21 days. In these three trials, patients had a median duration of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> of 19 years and a median baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency of 8 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per 28 days. Two-thirds (69%) of subjects used 2 concomitant AEDs and 28% used 1 concomitant AED. The most commonly used AEDs were carbamazepine (50%), lamotrigine (24%), valproic acid (21%), and levetiracetam (18%). Oxcarbazepine was not allowed as a concomitant AED.
</p>
<p>Studies 3 and 4 compared dosages of APTIOM 400, 800, and 1200 mg once daily with placebo. Study 5 compared dosages of APTIOM 800 and 1200 mg once daily with placebo. In all three trials, following an 8-week Baseline Phase, which established a baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency, subjects were randomized to a treatment arm. Patients entered a treatment period consisting of an initial titration phase (2 weeks), and a subsequent maintenance phase (12 weeks).   The specific titration schedule differed amongst the three studies.  Thus, patients were started on a daily dose of 400 mg or 800 mg and subsequently increased by 400 mg/day following one or two weeks, until the final daily target dose was achieved.
</p>
<p>The standardized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency during the Maintenance Phase over 28 days was the primary efficacy endpoint in all three trials. <a href="#t4">Table 4</a> presents the results for the primary endpoint, as well as the secondary endpoint of percent reduction from baseline in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency.  The APTIOM treatment at 400 mg/day was studied in Studies 3 and 4 and did not show significant treatment effect. A statistically significant effect was observed with APTIOM treatment at doses of 800 mg/day in Studies 3 and 4, but not in Study 5, and at doses of 1200 mg/day in all 3 studies.
</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Standardized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency During the Maintenance Phase Over 28 Days and Percent Reduction from Baseline in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency
</span></caption>
<col align="left" width="41.535%">
<col align="left" width="19.155%">
<col align="left" width="19.755%">
<col align="left" width="19.555%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"></th>
<th class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><span class="Bold">Placebo</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">APTIOM</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">800 mg</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">1200 mg</span></th>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">*statistically significant compared to placebo
</p></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">Study 3</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">N
</td>
<td class="Botrule Rrule" align="center" valign="top">95
</td>
<td class="Botrule Rrule" align="center" valign="top">88
</td>
<td class="Botrule Rrule" align="center" valign="top">87
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency (LS Mean <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per 28 days)<br>(p-value)
</td>
<td class="Botrule Rrule" align="center" valign="top">6.6
</td>
<td class="Botrule Rrule" align="center" valign="bottom">5.0<br><br>(0.047<span class="Sup">*</span>)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.3<br><br>(0.001<span class="Sup">*</span>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Percent Reduction from Baseline in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency (%)
</td>
<td class="Botrule Rrule" align="center" valign="top">-15
</td>
<td class="Botrule Rrule" align="center" valign="top">-36
</td>
<td class="Botrule Rrule" align="center" valign="top">-39
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">Study 4</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">N
</td>
<td class="Botrule Rrule" align="center" valign="top">99
</td>
<td class="Botrule Rrule" align="center" valign="top">87
</td>
<td class="Botrule Rrule" align="center" valign="top">81
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency (LS Mean <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per 28 days)<br>(p-value)
</td>
<td class="Botrule Rrule" align="center" valign="top">8.6
</td>
<td class="Botrule Rrule" align="center" valign="top">6.2<br><br>(0.006<span class="Sup">*</span>)
</td>
<td class="Botrule Rrule" align="center" valign="top">6.6<br><br>(0.042<span class="Sup">*</span>)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Percent Reduction from Baseline in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency (%)
</td>
<td class="Botrule Rrule" align="center" valign="top">-6
</td>
<td class="Botrule Rrule" align="center" valign="top">-33
</td>
<td class="Botrule Rrule" align="center" valign="top">-28
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="4" valign="top"><span class="Bold">Study 5</span></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">N
</td>
<td class="Botrule Rrule" align="center" valign="top">212
</td>
<td class="Botrule Rrule" align="center" valign="top">200
</td>
<td class="Botrule Rrule" align="center" valign="top">184
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency (LS Mean <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per 28 days)
</td>
<td class="Rrule" align="center" valign="top">7.9
</td>
<td class="Rrule" align="center" valign="top">6.5
</td>
<td class="Rrule" align="center" valign="top">6.0
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">(p-value)
</td>
<td class="Botrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">(0.058)
</td>
<td class="Botrule Rrule" align="center" valign="top">(0.004<span class="Sup">*</span>)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Median Percent Reduction from Baseline in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Frequency (%)
</td>
<td class="Botrule Rrule" align="center" valign="top">-22
</td>
<td class="Botrule Rrule" align="center" valign="top">-30
</td>
<td class="Botrule Rrule" align="center" valign="top">-36
</td>
</tr>
</tbody>
</table>
<p><a href="#fig5">Figure 5</a> shows changes from baseline in the 28-day total partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency by category of reduction in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency from baseline for patients treated with APTIOM and placebo in an integrated analysis across the three clinical trials. Patients in whom the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency increased are shown to the left as “Worse.? Patients in whom the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency decreased are shown in four categories.
</p>
<p><a name="fig5"></a><span class="Bold">Figure 5: Proportion of Patients by Category of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Reduction for APTIOM and Placebo Across All Three Double-blind Trials</span></p>
<p><a name="f07"></a><img alt="Figure 5
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-07.jpg"></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s79"></a><a name="section-15"></a><p></p>
<h1>15 REFERENCES
</h1>
<p class="First">French JA, Wang S, Warnock B, Temkin N. <span class="Italics">Historical control monotherapy design in the treatment of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</span> Epilepsia 2010;51(10):1936-43.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s80"></a><a name="section-16"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">APTIOM tablets are white, oblong and with functional scoring on one side (200 mg, 600 mg, and 800 mg) or white, circular bi-convex and plain on one side (400 mg) and identified with strength-specific one-sided engraving on the other side, “ESL 200? (200 mg), “ESL 400? (400 mg), “ESL 600? (600 mg), or “ESL 800? (800 mg). Tablets are supplied in the following strengths and package configurations (<a href="#t5">Table 5</a>):
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5: Package Configuration for APTIOM Tablets
</span></caption>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Tablet Strength</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">Package Configuration</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><span class="Bold">NDC Code</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">200 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">Bottles of 30
</td>
<td class="Botrule Rrule" align="center" valign="top">63402-202-30
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">400 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">Bottles of 30
</td>
<td class="Botrule Rrule" align="center" valign="top">63402-204-30
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle">600 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">Bottles of 60
</td>
<td class="Botrule Rrule" align="center" valign="top">63402-206-60
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Bottles of 90
</td>
<td class="Botrule Rrule" align="center" valign="top">63402-206-90
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="2" valign="middle">800 mg
</td>
<td class="Botrule Rrule" align="center" valign="top">Bottles of 30
</td>
<td class="Botrule Rrule" align="center" valign="top">63402-208-30
</td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top">Bottles of 90
</td>
<td class="Botrule Rrule" align="center" valign="top">63402-208-90
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="s81"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Italics">Storage</span></p>
<p>Store APTIOM tablets at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) <span class="Italics">[see USP Controlled Room Temperature].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s82"></a><a name="section-17"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See FDA-approved patient labeling (<a href="#s92">Medication Guide</a>).
</p>
<p>Inform patients of the availability of a Medication Guide, and instruct them to read the Medication Guide prior to taking APTIOM.  Instruct patients to take APTIOM only as prescribed.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s83"></a><a name="section-17.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</span></p>
<p>Counsel patients, their caregivers, and families that AEDs, including APTIOM, may increase the risk of suicidal thoughts and behavior and advise them of the need to be alert for the emergence or worsening of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Instruct patients, caregivers, and families to report behaviors of concern immediately to healthcare providers <span class="Italics">[see Warnings and Precautions (<a href="#s12">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s84"></a><a name="section-17.2"></a><p></p>
<p class="First"><span class="Underline">Serious Dermatologic Reactions</span></p>
<p>Advise patients and caregivers about the risk of potentially fatal serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.  Educate patients about the signs and symptoms that may signal a serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span>.  Instruct patients to consult with their healthcare provider immediately if a <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occurs during treatment with APTIOM <span class="Italics">[see Warnings and Precautions (<a href="#s13">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s85"></a><a name="section-17.3"></a><p></p>
<p class="First"><span class="Underline">DRESS/Multi-organ <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p>Instruct patients that a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> associated with signs of other organ system involvement (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, hepatic dysfunction) may be drug-related and should be reported to their healthcare provider immediately <span class="Italics">[see Warnings and Precautions (<a href="#s14">5.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s86"></a><a name="section-17.4"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></p>
<p>Advise patients of life threatening symptoms suggesting <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, eyes, lips, tongue, or difficulty in swallowing or breathing) that can occur with APTIOM.  Instruct them to immediately report these symptoms to their healthcare provider <span class="Italics">[see Warnings and Precautions (<a href="#s15">5.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s87"></a><a name="section-17.5"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></span></p>
<p>Advise patients that APTIOM may reduce serum sodium concentrations, especially if they are taking other medications that can lower sodium.  Advise patients to report symptoms of low sodium such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, or more frequent or more severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> <span class="Italics">[see Warnings and Precautions (<a href="#s16">5.5</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s88"></a><a name="section-17.6"></a><p></p>
<p class="First"><span class="Underline">Neurological Adverse Reactions</span></p>
<p>Counsel patients that APTIOM may cause <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, cognitive dysfunction, and visual changes.  These adverse reactions, if observed, are more likely to occur during the titration period compared to the maintenance period. Advise patients not to drive or operate machinery until they have gained sufficient experience on APTIOM to gauge whether it adversely affects their ability to drive or operate machinery <span class="Italics">[see Warnings and Precautions (<a href="#s17">5.6</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s89"></a><a name="section-17.7"></a><p></p>
<p class="First"><span class="Underline">Withdrawal of APTIOM</span></p>
<p>Advise patients not to discontinue use of APTIOM without consulting with their healthcare provider.  APTIOM should be gradually withdrawn to minimize the potential of increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency and <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span> <span class="Italics">[see Warnings and Precautions (<a href="#s23">5.7</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s90"></a><a name="section-17.8"></a><p></p>
<p class="First"><span class="Underline">Interaction with Oral Contraceptives</span></p>
<p>Inform patients that APTIOM can significantly decrease the effectiveness of hormonal contraceptives.  Recommend that female patients of childbearing potential use additional or alternative non-hormonal forms of contraception during treatment with APTIOM and after treatment has been discontinued for at least one menstrual cycle or until otherwise instructed by their healthcare provider <span class="Italics">[see Drug Interactions (<a href="#s35">7.3</a>, <a href="#s36">7.4</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s91"></a><a name="section-17.9"></a><p></p>
<p class="First"><span class="Underline">Pregnancy Registry</span></p>
<p>Encourage patients to enroll in the North American Antiepileptic Drug Pregnancy Registry if they become pregnant. This Registry is collecting information about the safety of AEDs during pregnancy.  To enroll, patients can call 1-888-233-2334 (toll-free) <span class="Italics">[see Use in Specific Populations (<a href="#s38">8.1</a>)].</span></p>
<p>SUNOVION
</p>
<p>Manufactured for:<br>Sunovion Pharmaceuticals Inc.<br>Marlborough, MA 01752 USA
</p>
<p>Under license from Bial
</p>
<p>© 2015 Sunovion Pharmaceuticals Inc.  All rights reserved.
</p>
<p>901716R01
</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s92"></a><a name="section-18"></a><p></p>
<table width="100%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<col align="left" width="12.500%">
<tfoot><tr class="First Last">
<td align="left" colspan="7" valign="top"><p class="First Footnote">This Medication Guide has been approved by the U.S. Food and Drug Administration.
</p></td>
<td align="left" valign="top"><p class="First Footnote">Revised 08/2015
</p></td>
</tr></tfoot>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="8" valign="top">
<span class="Bold">MEDICATION GUIDE</span><br><span class="Bold">APTIOM (ap  tee'  om)</span><br><span class="Bold">(eslicarbazepine acetate)</span><br><span class="Bold">tablets</span>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top">
<p class="First"><a name="p01"></a><span class="Bold">What is the most important information I should know about APTIOM?</span></p>
<ul class="Disc"><li>
<span class="Bold">Do not stop taking APTIOM without first talking to your healthcare provider.</span><ul class="Circle"><li>Stopping APTIOM suddenly can cause serious problems.  Stopping a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medicine suddenly in a patient who has <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that will not stop (<span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>).
</li></ul>
</li></ul>
<span class="Bold">1. Like other antiepileptic drugs, APTIOM may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.</span><br>Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:<br><br>
</td></tr>
<tr>
<td class="Lrule" align="left" colspan="4" valign="top"><ul class="Circle">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying
</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>
</li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>
</li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)
</li>
<li>acting aggressive, being angry, or violent
</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)
</li>
</ul></td>
<td class="Rrule" align="left" colspan="4" valign="top"><ul class="Circle">
<li>attempt to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>
</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>
</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>
</li>
<li>acting on dangerous impulses
</li>
<li>other unusual changes in behavior or mood
</li>
</ul></td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions?</span><br><ul class="Circle">
<li>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.
</li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.
</li>
<li>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.
</li>
</ul>Suicidal thoughts or actions may be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.<br><br><span class="Bold">2. APTIOM may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> or serious problems which may affect organs and other parts of your body like the liver or blood cells.  You may or may not have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with these types of reactions.</span><br>Call your healthcare provider right away if you have any of the following:
</td></tr>
<tr>
<td class="Lrule" align="left" colspan="4" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, eyes, lips, or tongue
</li>
<li>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">swollen glands</span>, or <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> that do not go away or come and go
</li>
<li>yellowing of your skin or eyes
</li>
<li>severe <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>
</li>
</ul></td>
<td class="Rrule" align="left" colspan="4" valign="top"><ul class="Circle">
<li>trouble swallowing or breathing
</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>
</li>
<li>painful sores in the mouth or around your eyes
</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>
</li>
<li>severe <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>
</li>
<li>frequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that do not go away
</li>
</ul></td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top"><ul class="Disc"><li>
<span class="Bold">APTIOM may cause the level of sodium in your blood to be low.  Symptoms of low blood sodium include:</span><br>
</li></ul></td></tr>
<tr>
<td class="Lrule" align="left" colspan="4" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>
</li>
</ul></td>
<td class="Rrule" align="left" colspan="4" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, lack of energy
</li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>
</li>
<li>more frequent or more severe <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>
</li>
</ul></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">Some medicines can also cause low sodium in your blood.  Be sure to tell your healthcare provider about all the other medicines that you are taking.
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">What is APTIOM?</span><br>APTIOM is a prescription medicine used alone or with other medicines to treat partial-onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.<br>It is not known if APTIOM is safe and effective in children under 18 years of age.
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">Who should not take APTIOM?</span><br>Do not take APTIOM if you are allergic to eslicarbazepine acetate, any of the other ingredients in APTIOM, or oxcarbazepine.  See the end of this Medication Guide for a complete list of ingredients in APTIOM.
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">What should I tell my healthcare provider before taking APTIOM?</span><br><span class="Bold">Before taking APTIOM, tell your healthcare provider about all your medical conditions, including if you:</span><ul class="Disc">
<li>have or have had suicidal thoughts or actions, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or mood problems
</li>
<li>have liver problems
</li>
<li>have kidney problems
</li>
<li>are allergic to oxcarbazepine.  Some people who are allergic to oxcarbazepine may also be allergic to APTIOM.
</li>
<li>use birth control medicine.  APTIOM may cause your birth control medicine to be less effective.  Talk to your healthcare provider about the best birth control method to use.
</li>
<li>are pregnant or plan to become pregnant.  APTIOM may harm your unborn baby.  Tell your healthcare provider right away if you become pregnant while taking APTIOM.  You and your healthcare provider will decide if you should take APTIOM while you are pregnant.<ul class="Circle"><li>If you become pregnant while taking APTIOM, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry.  The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy.  You can enroll in this registry by calling 1-888-233-2334.
</li></ul>
</li>
<li>are breastfeeding or plan to breastfeed.  APTIOM passes into breast milk.  You and your healthcare provider should discuss whether you should take APTIOM or breastfeed.
</li>
</ul>
<span class="Bold">Tell your healthcare provider about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements.<br>Taking APTIOM with certain other medicines may cause side effects or affect how well they work.  Do not start or stop other medicines without talking to your healthcare provider.<br>Especially tell your healthcare provider if you take:
</td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><ul class="Circle">
<li>oxcarbazepine
</li>
<li>phenobarbital
</li>
</ul></td>
<td align="left" colspan="2" valign="top"><ul class="Circle">
<li>carbamazepine
</li>
<li>phenytoin
</li>
</ul></td>
<td align="left" colspan="2" valign="top"><ul class="Circle">
<li>simvastatin
</li>
<li>birth control medicine
</li>
</ul></td>
<td align="left" colspan="2" valign="top"><ul class="Circle">
<li>omeprazole
</li>
<li>rosuvastatin
</li>
</ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Circle">
<li>clobazam
</li>
<li>primidone
</li>
</ul></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure.<br>Know the medicines you take.  Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">How should I take APTIOM?</span><br><ul class="Disc">
<li>Take APTIOM exactly as your healthcare provider tells you to take it.
</li>
<li>Do not stop taking APTIOM without talking to your healthcare provider.  Stopping APTIOM suddenly can cause serious problems, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that will not stop (<span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>).
</li>
<li>Your healthcare provider may change your dose.
</li>
<li>Your healthcare provider will tell you how much APTIOM to take.
</li>
<li>APTIOM can be taken with or without food.
</li>
<li>APTIOM can be taken as a whole tablet or crushed.
</li>
<li>If you take too much APTIOM, call your healthcare provider or go to the nearest hospital emergency room right away.
</li>
<li>Talk with your healthcare provider about what you should do if you miss a dose.
</li>
</ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">What should I avoid while taking APTIOM?</span><br><ul class="Disc"><li>Do not drive, operate heavy machinery, or do dangerous activities until you know how APTIOM affects you.  APTIOM may slow your thinking and motor skills.
</li></ul>
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">What are the possible side effects of APTIOM?</span><br>See <span class="Bold">“<a href="#p01">What is the most important information I should know about APTIOM?</a>?</span><br><span class="Bold">APTIOM may cause other serious side effects including:</span><br><ul class="Disc"><li>
<span class="Bold">Nervous system problems.</span>  APTIOM may cause problems that can affect your nervous system.  Symptoms of nervous system problems include:
</li></ul>
</td></tr>
<tr>
<td class="Lrule" align="left" colspan="2" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</li>
<li>trouble concentrating
</li>
</ul></td>
<td align="left" colspan="4" valign="top"><ul class="Circle">
<li>trouble walking or with coordination
</li>
<li>vision problems
</li>
</ul></td>
<td class="Rrule" align="left" colspan="2" valign="top"><ul class="Circle"><li>feeling <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> and tired
</li></ul></td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top"><ul class="Disc"><li>
<span class="Bold">Liver problems.</span>  APTIOM may affect your liver.  Symptoms of liver problems include:
</li></ul></td></tr>
<tr>
<td class="Lrule" align="left" colspan="2" valign="top"><ul class="Circle">
<li>yellowing of your skin or the whites of your eyes
</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>
</li>
</ul></td>
<td align="left" colspan="4" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</li>
<li>dark urine
</li>
</ul></td>
<td class="Rrule" align="left" colspan="2" valign="top"><ul class="Circle"><li>loss of appetite
</li></ul></td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">Get medical help right away if you have any of the symptoms listed above or listed in “<a href="#p01">What is the most important information I should know about APTIOM?</a>?</span><br><span class="Bold">The most common side effects of APTIOM include:</span>
</td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</li>
</ul></td>
<td align="left" colspan="2" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>
</li>
<li>feeling tired
</li>
</ul></td>
<td align="left" colspan="2" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>
</li>
</ul></td>
<td align="left" colspan="2" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>
</li>
</ul></td>
<td class="Rrule" align="left" valign="top"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>
</li>
<li>problems with coordination
</li>
</ul></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">Tell your healthcare provider if you have any side effect that bothers you or that does not go away.<br>These are not all the possible side effects of APTIOM.  For more information, ask your healthcare provider or pharmacist.<br>Call your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088.
</td></tr>
<tr><td class="Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">How should I store APTIOM?</span><br><ul class="Disc">
<li>Store APTIOM at 68°F to 77°F (20°C to 25°C).
</li>
<li>Safely throw away medicine that is out of date or no longer needed.
</li>
</ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top"><span class="Bold">Keep APTIOM and all medicines out of reach of children.</span></td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">What are the ingredients in APTIOM?</span><br><span class="Bold">Active ingredient:</span>  eslicarbazepine acetate<br><span class="Bold">Inactive ingredients:</span>  povidone, croscarmellose sodium, and magnesium stearate.
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">
<span class="Bold">General information about the safe and effective use of APTIOM.</span><br>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use APTIOM for a condition for which it was not prescribed. Do not give APTIOM to other people, even if they have the same symptoms that you have. It may harm them.<br>This Medication Guide summarizes the most important information about APTIOM.  If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about APTIOM that is written for health professionals.<br>For more information, go to www.aptiom.com or call 1-888-394-7377.
</td></tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="8" valign="top">SUNOVION<br>Manufactured for: Sunovion Pharmaceuticals Inc., Marlborough, MA 01752 USA<br>Under license from Bial<br>© 2015 Sunovion Pharmaceuticals Inc.  All rights reserved.
</td></tr>
</tbody>
</table>
<p class="First">______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s93"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 200 MG 30 COUNT OBLONG BOTTLE</span></p>
<p>NDC 63402-202-30
</p>
<p>30 Tablets
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>200 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Each time Aptiom is <br>dispensed give the patient the accompanying <br>Medication Guide.
</p>
<div class="Figure">
<a name="f08"></a><img alt="PRINCIPAL DISPLAY PANEL – 200 MG 30 COUNT OBLONG BOTTLE
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-08.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s94"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 400 MG 30 COUNT OBLONG BOTTLE</span></p>
<p>NDC 63402-204-30
</p>
<p>30 Tablets
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>400 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Each time Aptiom is
</p>
<p>dispensed give the patient the accompanying
</p>
<p>Medication Guide.
</p>
<div class="Figure">
<a name="f09"></a><img alt="PRINCIPAL DISPLAY PANEL – 400 MG 30 COUNT OBLONG BOTTLE
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-09.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s95"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 600 MG 60 COUNT OBLONG BOTTLE</span></p>
<p>NDC 63402-206-60
</p>
<p>60 Tablets
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>600 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Each time Aptiom is
</p>
<p>dispensed give the patient the accompanying
</p>
<p>Medication Guide.
</p>
<div class="Figure">
<a name="f10"></a><img alt="PRINCIPAL DISPLAY PANEL – 600 MG 60 COUNT OBLONG BOTTLE
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-10.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s96"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 800 MG 30 COUNT OBLONG BOTTLE</span></p>
<p>NDC 63402-208-30
</p>
<p>30 Tablets
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>800 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Each time Aptiom is
</p>
<p>dispensed give the patient the accompanying
</p>
<p>Medication Guide.
</p>
<div class="Figure">
<a name="f11"></a><img alt="PRINCIPAL DISPLAY PANEL – 800 MG 30 COUNT OBLONG BOTTLE
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-11.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s97"></a><a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 400 MG SAMPLE WALLET</span></p>
<p>400 mg
</p>
<p>per tablet
</p>
<p>NDC 63402-204-07
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>400 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Dispense the enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>This package contains 7 tablets.
</p>
<p>Professional Sample
</p>
<p>Not for Sale or Reimbursement
</p>
<div class="Figure">
<a name="f12"></a><img alt="PRINCIPAL DISPLAY PANEL – 400 MG SAMPLE WALLET
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-12.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s98"></a><a name="section-24"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 600 MG SAMPLE WALLET</span></p>
<p>600 mg
</p>
<p>per tablet
</p>
<p>NDC 63402-206-07
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>600 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Dispense the enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>This package contains 7 tablets.
</p>
<p>Professional Sample
</p>
<p>Not for Sale or Reimbursement
</p>
<div class="Figure">
<a name="f13"></a><img alt="PRINCIPAL DISPLAY PANEL – 600 MG SAMPLE WALLET
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-13.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s99"></a><a name="section-25"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 800 MG SAMPLE WALLET</span></p>
<p>800 mg
</p>
<p>per tablet
</p>
<p>NDC 63402-208-07
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>800 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Dispense the enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>This package contains 7 tablets.
</p>
<p>Professional Sample
</p>
<p>Not for Sale or Reimbursement
</p>
<div class="Figure">
<a name="f14"></a><img alt="PRINCIPAL DISPLAY PANEL – 800 MG SAMPLE WALLET
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-14.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s100"></a><a name="section-26"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – TITRATION SAMPLE PACK WALLET</span></p>
<p>400 mg
</p>
<p>per tablet and
</p>
<p>800 mg
</p>
<p>per tablet
</p>
<p>Titration Sample Pack
</p>
<p>NDC 63402-248-14
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>400 mg and 800 mg
</p>
<p>Rx Only
</p>
<p>ATTENTION DISPENSER: Dispense the enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>This package contains 14 tablets (7 tablets of 400 mg
</p>
<p>and 7 tablets of 800 mg).
</p>
<p>Professional Sample
</p>
<p>Not for Sale or Reimbursement
</p>
<div class="Figure">
<a name="f15"></a><img alt="PRINCIPAL DISPLAY PANEL – TITRATION SAMPLE PACK WALLET
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-15.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s101"></a><a name="section-27"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 400 MG SAMPLE CARTON</span></p>
<p>NDC 63402-204-28
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>400 mg
</p>
<p>ATTENTION DISPENSER: Dispense an enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>Rx Only
</p>
<p>This package contains 28 tablets on 4 sample cards.
</p>
<p>Each sample card contains 7 tablets each.
</p>
<p>Please see the enclosed full Prescribing Information.
</p>
<p>400 mg
</p>
<p>per tablet
</p>
<p>Professional Samples
</p>
<p>Not for Sale or
</p>
<p>Reimbursement
</p>
<div class="Figure">
<a name="f16"></a><img alt="PRINCIPAL DISPLAY PANEL – 400 MG SAMPLE CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-16.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s102"></a><a name="section-28"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 600 MG SAMPLE CARTON</span></p>
<p>NDC 63402-206-28
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>600 mg
</p>
<p>ATTENTION DISPENSER: Dispense an enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>Rx Only
</p>
<p>This package contains 28 tablets on 4 sample cards.
</p>
<p>Each sample card contains 7 tablets each.
</p>
<p>Please see the enclosed full Prescribing Information.
</p>
<p>600 mg
</p>
<p>per tablet
</p>
<p>Professional Samples
</p>
<p>Not for Sale or
</p>
<p>Reimbursement
</p>
<div class="Figure">
<a name="f17"></a><img alt="PRINCIPAL DISPLAY PANEL – 600 MG SAMPLE CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-17.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s103"></a><a name="section-29"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – 800 MG SAMPLE CARTON</span></p>
<p>NDC 63402-208-28
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>800 mg
</p>
<p>ATTENTION DISPENSER: Dispense an enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>Rx Only
</p>
<p>This package contains 28 tablets on 4 sample cards.
</p>
<p>Each sample card contains 7 tablets each.
</p>
<p>Please see the enclosed full Prescribing Information.
</p>
<p>800 mg
</p>
<p>per tablet
</p>
<p>Professional Samples
</p>
<p>Not for Sale or
</p>
<p>Reimbursement
</p>
<div class="Figure">
<a name="f18"></a><img alt="PRINCIPAL DISPLAY PANEL – 800 MG SAMPLE CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-18.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s104"></a><a name="section-30"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL – TITRATION SAMPLE PACK CARTON</span></p>
<p>NDC 63402-248-56
</p>
<p>ONCE DAILY
</p>
<p>Aptiom<span class="Sup">®</span></p>
<p>(eslicarbazepine acetate) Tablets
</p>
<p>400 mg and 800 mg
</p>
<p>ATTENTION DISPENSER: Dispense an enclosed
</p>
<p>Medication Guide to each patient.
</p>
<p>Rx Only
</p>
<p>This package contains 56 tablets in 4 titration sample packs.
</p>
<p>Each titration sample pack contains 14 tablets
</p>
<p>(7 tablets of 400 mg and 7 tablets of 800 mg).
</p>
<p>Please see the enclosed full Prescribing Information.
</p>
<p>400 mg
</p>
<p>per tablet and
</p>
<p>800 mg
</p>
<p>per tablet
</p>
<p>Titration Sample Pack
</p>
<p>Professional Samples
</p>
<p>Not for Sale or
</p>
<p>Reimbursement
</p>
<div class="Figure">
<a name="f19"></a><img alt="PRINCIPAL DISPLAY PANEL – TITRATION SAMPLE PACK CARTON
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d0c9554-eaeb-4694-8089-00133fcadce3&amp;name=apt03-0006-19.jpg">
</div>
<p>______________________________________________________________________________
</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-202</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESLICARBAZEPINE ACETATE</strong> (ESLICARBAZEPINE) </td>
<td class="formItem">ESLICARBAZEPINE ACETATE</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ESL;200
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-202-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-204</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESLICARBAZEPINE ACETATE</strong> (ESLICARBAZEPINE) </td>
<td class="formItem">ESLICARBAZEPINE ACETATE</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ESL;400
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-204-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63402-204-28</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63402-204-07</td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-206</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESLICARBAZEPINE ACETATE</strong> (ESLICARBAZEPINE) </td>
<td class="formItem">ESLICARBAZEPINE ACETATE</td>
<td class="formItem">600 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ESL;600
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-206-60</td>
<td class="formItem">60  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63402-206-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63402-206-28</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63402-206-07</td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-208</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESLICARBAZEPINE ACETATE</strong> (ESLICARBAZEPINE) </td>
<td class="formItem">ESLICARBAZEPINE ACETATE</td>
<td class="formItem">800 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ESL;800
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-208-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63402-208-90</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63402-208-28</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63402-208-07</td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-248</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-248-56</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-248-14</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">7 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK </td>
<td class="formItem">7 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-204</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESLICARBAZEPINE ACETATE</strong> (ESLICARBAZEPINE) </td>
<td class="formItem">ESLICARBAZEPINE ACETATE</td>
<td class="formItem">400 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ESL;400
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-204-17</td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>APTIOM 		
					</strong><br><span class="contentTableReg">eslicarbazepine acetate tablet</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63402-208</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESLICARBAZEPINE ACETATE</strong> (ESLICARBAZEPINE) </td>
<td class="formItem">ESLICARBAZEPINE ACETATE</td>
<td class="formItem">800 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K29/32</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ESL;800
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63402-208-17</td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022416</td>
<td class="formItem">04/07/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sunovion Pharmaceuticals Inc.
							(131661746)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e693597c-516c-4480-9185-616584ba3cf1</div>
<div>Set id: 3d0c9554-eaeb-4694-8089-00133fcadce3</div>
<div>Version: 6</div>
<div>Effective Time: 20150904</div>
</div>
</div> <div class="DistributorName">Sunovion Pharmaceuticals Inc.</div></p>
</body></html>
